Melodiol Global Health's operational progress update

Melodiol Global Health Limited (ASX: $ME1) continues to make strong operational progress through its Canadian subsidiary, Mernova. The company has achieved additional product launches across various provinces and signed an agreement with Best Kind Edibles for the manufacturing of cannabis edibles. The unaudited Q1 revenues of $1.75m and FY23 full year revenues of $6.9m reflect the ongoing strength of the Ritual brand.

Executive Commentary on Operational Progress

Mernova continues to deliver strong revenue figures, and we are very proud of the team for their ongoing commitment to high-quality cannabis. We look forward to generating further purchase orders as new products and formats become available. - CEO and Managing Director, Mr William Lay

Summary of Melodiol Global Health's Announcement

Melodiol Global Health (ASX: $ME1) has reported strong operational progress through its subsidiary, Mernova, with additional product launches and a new agreement for the manufacturing of cannabis edibles. The unaudited Q1 revenues of $1.75m and FY23 full year revenues of $6.9m indicate the ongoing strength of the Ritual brand. CEO and Managing Director, Mr William Lay, expressed pride in the team's commitment to high-quality cannabis and anticipates further purchase orders as new products and formats become available. The company's focus on delivering high-quality cannabis and expanding its product suite reflects its ambition to meet the growing demand for its products and strains.